MRP14 is a protein that is speci®cally expressed in myeloid and epithelial cells during the stages of acute or chronic in¯ammatory states such as rheumatoid arthritis or sarcoidosis. MRP14 has EF-hand motifs as Ca 2+ -binding sites and belongs to the S100 family of proteins. This paper deals with the sample preparation (cloning, overexpression and puri®cation), crystallization and preliminary crystallographic analysis of recombinant human MRP14. Crystals of MRP14 were obtained by the hanging-drop vapour-diffusion method. MRP14 crystals belong to space group P2 1 , with unit-cell parameters a = 57.59, b = 178.44, c = 61.23 A Ê , = 113.17 , and diffract to 2.1 A Ê resolution.
Introduction
In®ltrating macrophages express speci®c proteins MRP14 and MRP8 in the event of acute or chronic in¯ammation (Odnik et al., 1987) . These proteins were originally isolated from human peripheral blood mononuclear cell cultures as part of a complex using a monoclonal antibody directed against human macrophage migration inhibitory factor (MIF) and were thus named MIF-related proteins (Burmeister et al., 1986) . These proteins have two EF-hand motifs as Ca 2+ -binding sites and belong to the S100 family, members of which have similar amino-acid sequences (Scha È fer & Heizmann, 1996) . Members of the S100 family of proteins have a strong tendency to dimerize and have been implicated in the Ca 2+ -dependent regulation of a variety of intracellular activities (Donato, 1999) . The S100 family of proteins were found to be expressed in a celland tissue-speci®c manner. Subsequent studies showed that they were associated with different human pathological states such as cancer, neurodegeneration and in¯ammatory disease (Donato, 1999) .
MRP14 and MRP8 are expressed with tight regulation in granulocytes, monocytes, neutrophils and keratinocytes during their differentiation (Lagasse & Clerc, 1988; Zwadlo et al., 1988) . Phagocytes expressing these proteins are found in a variety of in¯ammatory conditions including rheumatoid arthritis and allograft rejections (Goebeler et al., 1994) . In¯ammatory disorders such as chronic bronchitis and cystic ®brosis are associated with elevated plasma levels of MRP14 and MRP8 (Brun et al., 1994; Roth et al., 1992) . These proteins are co-expressed and it has been shown that these proteins associate in a Ca 2+dependent manner to form a non-covalent heterodimer (Teigelkamp et al., 1991) . The MRP8/14 heterocomplex exhibits speci®c biological functions such as inhibition of casein kinase (Murao et al., 1989) , fatty-acid binding (Roulin et al., 1999; Siegenthaler et al., 1997) and translocation to cytoskeleton and plasma membrane (Roth et al., 1993; van den Bos et al., 1996) in phagocytes under the in¯ammatory process. In this complex, MRP14 plays some indispensable roles (Murao et al., 1989; Roth et al., 1993; van den Bos et al., 1996) .
MRP14 has a relative molecular mass of 14 kDa and is composed of 114 amino acids. A distinguishing feature of MRP14 is its extended C-terminus, rendering it considerably larger than other S100-family members (with molecular masses of about 10 kDa; Kligman & Hilt, 1988 ). This C-terminal tail region of MRP14 is homologous in sequence and displays a function similar to that of a region of the plasma glycoprotein high molecular weight kininogen (HMWK; Hessian et al., 1995) and has also been reported to possess complete identity with the N-terminus of the neutrophil immobilizing factor (NIF; Freemont et al., 1989; Watt et al., 1983) . A recent report has also revealed that MRP14 selectively activates the 2 integrin Mac-1 (Newton & Hogg, 1998) . These facts suggest that MRP14 plays important roles in immobilizing leukocytes at the endothelial surface and in extravasation of leukocytes into tissues. Independent expression of MRP14 and its functions have also been reported ( 
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MRP14 is a protein that has an indispensable role in Ca 2+ -dependent functions during in¯ammation. Understanding of the structure of MRP14 is required in order to understand these functions on the molecular level.
We have previously analysed the crystal structure of human MRP8 (Ishikawa et al., 2000) . In this report, we present the ®rst crystallization and X-ray diffraction analysis of human MRP14 (hMRP14) protein.
Methods and results

Cloning, overexpression and purification
The gene encoding human MRP14 has already been identi®ed (Lagasse & Clerc, 1988) . The hMRP14 gene was ampli®ed by PCR using human cDNA prepared from human peripheral blood as a template DNA and inserted into a pET-3a vector (Novagen) via T-vector sub-cloning (pGEM-T Easy vector, Promega). The vector pET/hMRP14 was transformed into Escherichia coli B834 (DE3), the expression host cell. The cells were grown at 310 K. Overexpression of recombinant hMRP14 was induced by 1 mM IPTG. After the IPTG induction, the medium was incubated at 295 K for 14 h with shaking in order to prevent the formation of inclusion bodies of MRP14. The cells were harvested by centrifugation at 3500g for 20 min at 277 K and resuspended in buffer A (50 mM Tris±HCl pH 7.5 containing 0.1 mM PMSF, 1 mM DTT, 5 mM MgSO 4 and 1 mg DNaseI). The cells were disrupted by a French press (Amico Inc.) at 8.3 MPa and the homogenate was clari®ed by centrifugation at 14 000g for 1 h at 277 K. Ammonium sulfate was slowly added to the supernatant of the cell extract to 60% saturation and the solution was centrifuged at 8000g for 20 min at 277 K. The supernatant was then brought to 90% saturation and centrifuged. The protein pellet was resuspended in buffer B (50 mM Tris±HCl pH 7.5 containing 10 mM EDTA, 0.1 mM PMSF and 1 mM DTT) and dialyzed against the same buffer. MRP14 was puri®ed by anion-exchange chromatography using the Bio-CAD60 system equipped with a QE/L column (Applied Biosystems). The protein was eluted using a linear gradient of 0±1.0 M NaCl in a 20 mM Tris/bis-tris anionexchange standard buffer at pH 6.0. The fractions containing the target protein were dialyzed against buffer C (20 mM MOPS pH 6.8 containing 150 mM NaCl, 1 mM EDTA and 1 mM DTT), concentrated to 10 ml and loaded on a Hi-Load 26/60 Superdex75pg size-exclusion chromatography (SEC) column (Amersham Pharmacia Biotech). MRP14 was eluted as a single peak and the molecular weight estimated from the elution volume suggested that this protein exists as a dimer. The fraction containing MRP14 was pooled and dialyzed against MilliQ water containing 10 mM CaCl 2 and 1 mM DTT. After dialysis, the sample solution was concentrated by ultra®ltration using CentriPlus-3 and Centricon-3 (Amicon Inc.) to a ®nal concentration of 10 mg ml À1 . The purity of the puri®ed sample was analysed by MALDI-TOF mass spectrometry (Voyager DE-PRO, Applied Biosystems) and dynamic light scattering (Dyna-Pro, Protein Solutions Inc.).
Crystallization
All crystallization experiments were performed using the hanging-drop vapourdiffusion method in a 24-well tissue-culture Linbro plate (ICN Inc.) at 293 K. The initial crystallization condition screening was carried out using a reservoir consisting of 0.5 ml of Hampton Research Crystal Screens I and II. Each drop contained 2 ml reservoir solution and an equal volume of the protein solution. Crystals were obtained within 72 h under condition number 36 of Crystal Screen I (0.1 M Tris±HCl pH 8.5, 8% PEG 8K); these initial crystals were multi-crystal clusters. Further optimization of the conditions to improve crystals was performed. Optimization of the protein concentration and the mixing ratio of the reservoir solution and the protein solution were carried out. Screenings of additives to improve the quality of crystals were also performed using Additive Screens (Hampton Research); some amphiphiles improved MRP14 crystals. Further screening of detergents was carried out and the best single crystals were ®nally obtained with 0.1 M Tris±HCl pH 7.8±8.2, 1±2%(w/v) PEG 6K and 0.25± 1.75%(w/v) CHAPS (Fig. 1) .
Data collection and preliminary analysis
X-ray diffraction data were collected to 2.1 A Ê resolution at 100 K by¯ash-cooling 3.8 (3.9) I/'(I) 6.5 (2.5) R meas (%) 6.6 (33.9) ² R meas = h NaN À 1 1a2 j jhIhi À Ih j j/ h j hIhi, where N is the redundancy.
Figure 2
Amino-acid sequence alignment of hMRP14 and search models for the MR structure analysis. The hMRP14 is larger than other proteins because of its unique long C-terminal extension. crystallization papers after soaking in the cryoprotectant solution with 30%(v/v) glycerol on the SPring-8 beamline BL44B2. Data were processed using MOSFLM (Leslie, 1993) and SCALA from the CCP4 program suite (Collaborative Computational Project, Number 4, 1994) . A summary of the data is shown in Table 1 . The space group of this crystal was assigned as P2 1 , with unit-cell parameters a = 57.59, b = 178.44, c = 61.23 A Ê , = 113.17 . The asymmetric unit contains four dimers of MRP14, giving a crystal volume per protein mass (V M ; Matthews, 1968) of 2.7 A Ê 3 Da À1 and a solvent content of 54.9%.
We subsequently attempted to solve the MRP14 structure by the molecularreplacement (MR) method using other S100-family proteins as a search model with the program AMoRe (Navaza, 1994) from the CCP4 program suite (Collaborative Computational Project, Number 4, 1994) . Search models were selected from the X-ray crystal structures of the S100 family of proteins based on their sequence similarity to hMRP14. The models used were S100C (PDB code 1qls; Re Â ty et al., 2000), MRP8 (S100A8, PDB code 1mr8; Ishikawa et al., 2000) , S100B (1mho; Matsumura et al., 1998) and S100A12 (1e8a; Moroz et al., 2001) (27, 30, 34 and 43% identity, respectively, excluding C-terminal extension). However, these attempts did not yield any reasonable results. In comparison with other members of the S100 family (Fig. 2 ), MRP14 has a long C-terminal extension, which may in part explain the dif®culty in analysing the structure of this protein by the MR method.
Preparation of Se-Met MRP14 crystals for use with the multiple-wavelength anomalous dispersion (MAD) method is now in progress.
